IDRA-21

Details

Stereochemistry	RACEMIC
Molecular Formula	C8H9ClN2O2S
Molecular Weight	232.687
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1

InChI

InChIKey=VZRNTCHTJRLTMU-UHFFFAOYSA-N

InChI=1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3

HIDE SMILES / InChI

Molecular Formula	C8H9ClN2O2S
Molecular Weight	232.687
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Metabotropic glutamate receptor 5 39	Positive Allosteric Modulator 179		1.1 nM [EC50]

Substance Class	Chemical
Record UNII	689UW7PT68
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

IDRA-21

Code

English

IDRA21

Code

English

7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE 1,1-DIOXIDE

Systematic Name

English

2H-1,2,4-BENZOTHIADIAZINE, 7-CHLORO-3,4-DIHYDRO-3-METHYL-, 1,1-DIOXIDE

Systematic Name

English

7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-BENZO(E)(1,2,4)THIADIAZINE 1,1-DIOXIDE

Systematic Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

WIKIPEDIA

IDRA-21

PRIMARY

IDRA-21 is an ampakine drug and a benzothiadiazine derivative. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form. IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 1030 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine,(2)(3) and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain. IDRA-21 does not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

CAS

22503-72-6

PRIMARY

FDA UNII

689UW7PT68

PRIMARY

MANUFACTURER PRODUCT INFORMATION

IDRA-21

PRIMARY

IDRA-21 currently has only had animal trials. Dosing in a study with Patas Monkeys was 3 or 5.6 mg/kg p.o. in addition with 30 mg/kg p.o. of Aniracetam. This study indicated that IDRA-21 was 10-fold more potent than Aniracetam at reducing learning defects. A water maze study in rats showed cognitive enhancement at oral dosages of 4-120 mumol/kg. Human dosages have no history of peer-reviewed clinical studies. Some reading online suggested positive human activity at 5-25mg orally.

PUBCHEM

3688

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					689UW7PT68

IDRA-21

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next